Digital Monitoring in Cancer Survivors

Digital monitoring in cancer survivors WHY? There is a large amount of evidence to suggest that addressing a cancer patients' quality of life and symptoms has a positive impact on their wellbeing and experience with care. Finding ways of accurately and timely measuring Patient Reported Outcomes (PROs), along with developing electronic and mobile health (eHealth and mHealth) solutions, is being increasingly recognized as one way to manage patients' quality of life and symptoms without increasing burden on time and resource-stretched National Health Services. WHAT? The main objective of this study is to assess the feasibility of administering routine self assessment through questionnaire called the Edmonton Symptom Assessment System (ESAS) via MS Forms associated with continuous wearing of a smart watch in cancer survivors. We also hope to identify predictors of attrition or dissatisfaction. WHO? Adult outpatients with controlled cancer undergoing surveillance (cancer survivors) WHERE? Participants will be identified through attendance in oncology outpatient clinics by the oncologist in charge. HOW? Participants will receive a smart watch and smart phone (or an App downloaded onto their own phone). The smart watch will record physical activity , sleep patterns and other data such as heart rate and participants are expected to wear the watch all the time for about 4 months. Participants will also attend the hospital for a research appointment at the start and the end of the research and complete questionnaires weekly throughout the study, delivered via MS forms. At the end of the study the patients will be invited to a focus group to discuss their experience. The study will last for 18 months; each participants' involvement will be for about 4 month.

Sex

All

Minimum age

18 Years

Inclusion Criteria:

* • Diagnosis of any solid malignancy, at any stage

  * Completion of treatment (including surgery, radiotherapy, and any kind of cytotoxic systemic anticancer treatment \[hormonal and targeted treatments allowed\])
  * Clinical, biochemical and radiological confirmation of controlled disease (no evidence of residual disease or not-progressive disease)
  * Scheduled for either a therapeutic break (from cytotoxic systemic anticancer treatment), or having completed the planned multimodal treatment
  * Scheduled for active surveillance plan within oncology service or discharged to surgical or GP care following completion of adjuvant treatment
  * Male or female patients aged at least 18 years old
  * WHO Performance Status 0-2

Exclusion Criteria:

* • Not in possession of a SIM card

  * No internet access through Wi-Fi or unwilling to use mobile data allowance on a daily basis
  * Unable to understand and follow the instructions autonomously
  * Uncontrolled severe comorbidities (I.e., cardiovascular, neurological, respiratory)
  * Lack of capacity
  * Unable to understand English
  * Still undergoing systemic anticancer treatment (apart from bone-targeted agents, hormonal treatment against breast or prostate cancers or maintenance monoclonal antibody monotherapy)
  * Poor general condition (PS\>2)